cyrilzakka/clinical-trials huggingface dataset:
Mirror Therapy with Cutaneous Electrical Sensory Stimulation on Lower Limb Motor Functions in Stroke

This study aims to evaluate the effectiveness of concurrent mirror therapy (MT) and transcutaneous electrical nerve stimulation (TENS) in augmenting the efficacy of the lower limb task-oriented training in people with stroke. It is hypothesize that MT combined with TENS would be superior to sham-mirror therapy with TENS, or MT with placebo-TENS, or control training only in improving lower limb motor functions and walking ability in people with stroke when combined with the lower limb task-oriented training.

The application of transcutaneous electrical nerve stimulation (TENS) over a paretic lower limb could augment the effects of task-oriented exercise therapy on lower limb motor function in people with stroke, possibly through increased excitability of sensorimotor cortex.

In mirror therapy (MT), the intact limb performs motor tasks while its mirror reflection is superimposed over the covered paretic limb, creating a visual illusion of enhanced function over the paretic limb. The visual input during MT could substitute for reduced proprioceptive inputs and increase spatial attention of the paretic limb, which could improve motor function of the paretic limb, possibly through increased cortical activity in the lesioned hemisphere and mirror neurone system.

The next question concerns whether MT could be combined with TENS and whether their synergetic effects could maximise the motor output of paretic limbs in people with stroke.

Eligibility Criteria:
Inclusion Criteria:

1. have had a single stroke with ischemic brain injury or intracerebral haemorrhage diagnosed by magnetic resonance imaging or computed tomography within the previous 6 to 36 months;
2. have at least 5 degrees of active ankle dorsiflexion in the antigravity position;
3. are able to walk 10 m independently with or without a walking aid;
4. are able to score 6 or higher out of 10 on the abbreviated mental test;
5. have no unilateral neglect, hemianopia or apraxia;
6. have no skin allergy (e.g. redness or itchiness to the electrical stimulation pads) to electrical stimulation or electrodes; and
7. are able to follow instructions and give informed consent.

Exclusion Criteria:

1. have any additional medical, cardiovascular or orthopaedic condition that would hinder proper treatment or assessment;
2. have visual deficits that may hinder them from benefiting from the mirror visual feedback;
3. have receptive dysphasia; or
4. are involved in drug studies or other clinical trials.
Use of CBCT-based Tooth Replica in Tooth Autotransplantation to Improve the Outcome of Tooth Replacement in Children

The aim of this study lies in comparing the outcome of the proposed technique in a large sample size group to the outcome of the conventional tooth autotransplantation method and to provide sufficient evidence for improving the long-term success rate of the tooth autotransplantation procedure.


Eligibility Criteria:
Inclusion Criteria:

The subjects will be divided in two groups according to different surgical protocols.

1. Pediatric subjects (age between 9-18 years) treated with the CBCT-based replica procedure (prospective approach).

   Pediatric subjects (N=50) that missed their teeth due to agenesis or lost their permanent teeth due to trauma, caries, and endodontic failure and referred to dentistry department for replacement of the missing tooth by means of tooth autotransplantation.
2. Pediatric subjects (age between 9-18 years) treated with the conventional method (prospective and retrospective).

Pediatric subjects (N=50) that missed their teeth due to agenesis or lost their permanent teeth due to trauma, caries, and endodontic failure and referred to dentistry department for replacement of the missing tooth by means of tooth autotransplantation.

A matched control patient will be selected with the focus on a very similar surgical challenge, based on age, gender and a matching donor tooth with the same stage of root development and host bed.

Exclusion Criteria:

* Potential participants (case and control) will be excluded if follow-up data are missing for the one-year follow-up.
EPIDREAM 1 : Study of Dreaming in Epilepsy

Dreaming is a sleep-associated cognitive process whose neural substrates and functions remain poorly understood. In healthy subjects, the frequency of dream recall is influenced by several factors such as age, gender, interest in dreams and sleep quality. The content of dreams mainly depends on waking life experiences, especially when they are recent and have a strong emotional content. The function of dreams remains debated but it is widely accepted that dreams play a role in emotional regulation.

Modifications in dreams are observed in several neurological diseases and sleep disorders, due to the modifications of sleep related to these diseases, as well as to associated disturbances in cognitive functioning and to the impact on such diseases on waking life. Epilepsy is a neurological condition characterized by a predisposition to seizures resulting from excessive and synchronized abnormal brain activity; it is associated with numerous co-morbidities including sleep and cognitive disorders, which are present in nearly one in two patients. However, the influence of epilepsy on sleep-related cognitive processes is poorly understood. It is suspected that nocturnal epileptic activity disturbs sleep-related memory consolidation processes, but the consequences of epilepsy on dreams have been little investigated.

The study of the determinants (epilepsy syndrome, location of the epileptic focus, presence of sleep-related seizures, certain anti-epileptic treatments, alteration of the quality of sleep) of dream characteristics in this context could lead to a better understanding of the dreams physiology, the interactions between epilepsy and sleep, as well as the cognitive and emotional functioning related to sleep in epilepsy. It could also determine whether dream characteristics can provide information on the epilepsy syndrome and on the presence of nocturnal seizures, and thus constitute a diagnostic tool.

In this cross-sectional observational study, we aim to identify determinants of dream recall in relation to epilepsy by administering a simple and brief questionnaire on sleep and dreams, to all consecutive patients seen in epileptology consultation during 12 months. Our objectives are

1. To determine whether the presence of sleep-related seizures influences the frequency of dream recall in patients with epilepsy
2. To describe the characteristics of dreams in epilepsy, the influence of epilepsy on dreams and to characterize the determinants of dream recall frequency in patients with epilepsy We hypothesize that the presence of seizures during sleep will be associated with poorer sleep quality, increased frequency of dream recall, and that we will observe the inclusion of epilepsy symptoms in dream content, particularly in subjects who are aware of their nocturnal seizures and are awakened by them.


Eligibility Criteria:
Inclusion Criteria:

* Patient seen at the epilepsy consultation
* Age 18-65 years
* Certain diagnosis of epilepsy whatever the syndromic diagnosis and the frequency of seizures

Exclusion Criteria:

* major cognitive disorders
* refusal to participate
Inspiratory Muscle Training Combined With General Exercise Training in COPD

Chronic Obstructive Pulmonary Disease (COPD) is a frequent disease, with increasing prevalence. Pulmonary rehabilitation through general exercise training (GET) is a corner stone of COPD care. Inspiratory muscle training (IMT) as a stand-alone therapy decreases dyspnea and improves exercise capacity. Whether IMT combined with GET adds a supplementary benefit in the rehabilitation of COPD patients is however uncertain.

Prospective, parallel-group, randomized controlled trial

80 COPD patients will be randomized into two groups. One group will receive general exercise training combined with inspiratory muscle training, 3 times a week, for a total of 36 sessions. The other group will receive general exercise training combined with shame inspiratory muscle training, 3 times a week, for a total of 36 sessions.

We will assess the difference of improvement in exercise capacity between the 2 groups with the 6 minute walking test. We will also assess the difference of improvement in quality of life with St-George's respiratory questionnaire. Finally the difference of improvement in maximal inspiratory pressure will be determined.

Patients and investigators assessing the outcomes will be blinded to group allocation.

Written informed consent will be obtained from each subject. The data will be treated anonymously.

Eligibility Criteria:
Inclusion Criteria:

* COPD demonstrated by spirometry using Gold Criteria
* Patient referred by a pneumologist to the ambulatory pulmonary rehabilitation program at the Riviera-Chablais Hospital, Monthey
* Patient with maximal inspiratory pressure \< 60 cmH20
* Patient older than 40 years

Exclusion Criteria:

* Orthopaedic or neurological troubles that could slant the 6 minute walking test
Project Sexual Awareness for Everyone (SAFE)

This trial randomizes young Mexican American and African American women with a sexually transmitted infection to a behavioral intervention (3 three hour weekly sessions) versus control with the goal of preventing recurrent sexually transmitted infections.

Participants are interviewed, examined, and offered treatment at 0, 6, 12 months and as necessary.

Eligibility Criteria:
Inclusion Criteria:

* Mexican American,
* 14 - 45 years old,
* English Speaking,
* non-viral sexually transmitted infection

Exclusion Criteria:

* Non-English speaking,
* viral sexually transmitted infection
Screening Protocol for Preliminary Eligibility Determination for Adoptive Cell Therapy Trials

This screening study is intended to determine preliminary eligibility of participants who may be potential candidates for GlaxoSmithKline's Adoptive T-cell therapy studies by screening for appropriate biomarkers. No treatment intervention will occur as part of this screening study.


Eligibility Criteria:
Inclusion Criteria:

* Histologically or cytologically confirmed diagnosis of locally advanced high-risk eligible tumor types .
* Participant must be greater than or equal to (\>=)18 years of age (or \>=10 years of age with synovial sarcoma or myxoid/round cell liposarcoma \[MRCLS\])
* Participants with life expectancy of greater than 6 months
* Performance status: Eastern Cooperative Oncology Group 0-1.

Exclusion Criteria:

* Any prior treatment with oncology cell and/or gene therapy (unless agreed in advance with Sponsor)
* Prior malignancy not in complete remission.
* Clinically significant systemic illness
* Serious active infections or significant cardiac, pulmonary, hepatic or other organ dysfunction,
* Prior or active demyelinating disease
* Previous New-York Esophageal Antigen-1 (NY-ESO-1)-specific T cells, NY-ESO-1 vaccine, or NY-ESO-1 targeting antibody.
* Previous allogeneic hematopoietic stem cell transplant within the last 5 years or solid organ transplant.
Diet and Learning Abilities in Norwegian Youths

The aim of this study is to assess the effects of giving a schoolmeal with fatty fish, a schoolmeal without fish or omega-3 capsules on Noregian adolescents cognitive performance (concentration and learning abilities), mental health statua and markers of nutritional status. In addition, to disentangle the effect of fatty fish eaten as food and the effects of omega-3 fatty acids taken as a supplement.

There has been an increased attention to the role of nutrition for learning abilities among schoolchildren. As the diet provides humans with energy and several essential nutrients, a balanced supply of all nutrients promotes not only physical growth and health, but also cognitive development, helping children to learn from infancy throughout adolescence and beyond. In a three-armed non-blinded intervention trial the investigators will test whether ingestion of a schoolmeal or omega-3 capsules will improve cognitive function among pupils in 9th grade at eight lower secondary school. The pupils will be randomised into three groups, one group will be served lunch with fatty fish, one group will be served similar lunch with meat/cheese (without fish) and one group will recieve omega-3 capsules three times week over a period of 12 weeks. At the beginning and at the end of the study, pupils should conduct cognitive tests, and blood-, urine- and hair samples will be taken. The pupils should also answer a questionnaire on their diet, physical activity, sleep pattern and mental health.

Eligibility Criteria:
Inclusion Criteria:

* girls and boys at lower secondary schools (9th grade)

Exclusion Criteria:

* allergy or intolerance to the food or food ingredients in the study
Comparing Fluoroscopy and Technological Methods for Guidance During Endovascular Procedures

The investigators want to test a navigation system for guidance during insertion of stent graft in abdominal aortic aneurysms. The navigation system consists of software developed by SINTEF Health, a custom made catheter with a micro position sensor in the tip and an emitter than induces an electromagnetic field around the patient. Preoperative CT- and intraoperative DynaCT- data are reconstructed into 3 dimensional images. The 3 dimensional images are loaded into the navigation system. Then the magnetic field, in which the patient finds himself, is calibrated with the 3 dimensional images. When the catheter is inserted into the iliac artery and aorta, the position sensor (in the tip of the catheter) is displayed in real time at the exact anatomic location in the 3 dimensional image.

Null hypothesis (H0):

* Insertion of stent graft is performed equally satisfactorily with fluoroscopy alone as with both fluoroscopy and new navigation technology

Alternative hypothesis (H2):

* Insertion of stent graft is NOT performed equally satisfactorily with fluoroscopy alone as with both fluoroscopy and new navigation technology


Eligibility Criteria:
Inclusion Criteria:

* AAA with diameter \> 5,0 cm suitable for endovascular technique
* Normal creatinine
* \> 60 years of age

Exclusion Criteria:

* Known heart failure or unstable coronary disease
* Other morbidity than normally contraindicates endovascular treatment
Arthroscopic Bankart Repair With and Without Remplissage in Anterior Shoulder Instability

The purpose of this prospective, randomized, controlled trial is to compare subjective patient-reported outcomes and objective clinical results between arthroscopic Bankart repair with and without arthroscopic infraspinatus remplissage in patients with anterior shoulder instability with a Hill-Sachs Defect.

Significant osseous defects of the glenohumeral joint can often lead to failure of arthroscopic shoulder stabilization procedures. The best treatment in the setting of shoulder instability with significant glenoid and/or humeral defects remains controversial. Several open procedures have been suggested, but arthroscopic methods have started to garner some attention in the literature. In patients with an engaging Hill-Sachs lesion without significant glenoid bone loss, arthroscopic remplissage consisting of arthroscopic posterior capsulodesis and infraspinatus tenodesis to fill the Hill-Sachs lesion has been proposed as a novel treatment method.

The authors believe it is scientifically necessary to investigate the role of addition of arthroscopic infraspinatus remplissage to the conventional arthroscopic Bankart repair. As more surgeons are trained in the technique, it will be performed more frequently. Increased patient awareness continues to lead to increasing demand for minimally invasive approaches. Arthroscopic remplissage brings with it an increase in operative time, with a theorized risk of reduction in dislocation risk. For these reasons, the authors believe that it is scientifically and fiscally necessary to determine the difference in outcome between arthroscopic Bankart repair with and without arthroscopic infraspinatus remplissage for patients with anterior shoulder instability and a Hill-Sachs defect in the framework of a prospective, randomized controlled study.

Eligibility Criteria:
Inclusion Criteria:

* 14 years or older
* must have anterior shoulder instability and Hill-Sachs defect
* must have anterior instability with any engaging Hill Sachs Lesion on CT scan, MRI or ultrasound and no more than 15% glenoid bone loss

Exclusion Criteria:

* Glenoid defect \>15% of AP diameter of glenoid
* significant shoulder comorbidities (i.e, OA, previous surgery other than previous instability)
* active joint or systemic infection
* significant muscle paralysis
* rotator cuff or Charcot's arthropathy
* significant medical comorbidity that may alter effectiveness of surgical intervention
* major medical illness
* unable to speak French or English
* psychiatric illness that precludes informed consent
* unwilling to be followed for 2 years
Post Marketing Clinical Follow up Study for MagnetOs Putty in Patients With Degenerative Disc Disease

This study is a post-marketing clinical follow-up study for MagnetOs Putty. MagnetOs Putty is a synthetic bone-like material which is routinely used by surgeons as a treatment for patients with degenerative disc disease who will undergo surgery for spinal fusion (extreme lateral interbody fusion (XLIF). MagnetOs Putty will be used according to the instructions for use.


Eligibility Criteria:
Inclusion Criteria:

1. Written informed consent by the patient.
2. Male or female patient ≥ 25 up to and including 75 years old.
3. Patients with degenerative disc disease with up to grade 1 spondylolisthesis and with leg pain requiring 1 to 3 level laminectomy and a single/two-level fusion (L2 - S1). Degenerative disc disease is defined by the presence of one or more of the following:

   1. instability (angulation ≥ 5 degrees or translation ≥ 3 mm on flexion/extension radiographs),
   2. osteophyte formation of facet joints or vertebral endplates,
   3. decreased disc height by \> 2 mm, but dependent upon the spinal level,
   4. scarring/thickening of ligamentum flavum, annulus fibrosis or facet joint capsule,
   5. disc degeneration and/or herniation,
   6. facet degeneration,
   7. vacuum phenomenon.
4. Patients with an Oswestry Disability Index (ODI) score ≥ 30.
5. Patients with a Visual Analogue Scale (VAS) leg score ≥ 40.
6. Failed conservative treatment (physical therapy, bed rest, medications, spinal injections or transcutaneous electrical nerve stimulation) for a period of 6 months prior to study enrollment.

Exclusion Criteria:

Per the current Instruction For Use, MagnetOs Putty must not be used in the following clinical situations:

1. To treat conditions in which general bone grafting is not advisable.
2. In conditions where the surgical site may be subjected to excessive impact or stresses, including those beyond the load strength of fixation hardware (e.g. defect site stabilisation is not possible).
3. In case of significant vascular impairment proximal to the graft site.
4. In case of severe metabolic or systemic bone disorders that affect bone or wound healing.
5. In case of acute and chronic infections in the operated area (soft tissue infections; inflammation, bacterial bone diseases; osteomyelitis).
6. When intraoperative soft tissue coverage is not planned or possible.
7. In direct contact with the articular space.
8. In case of treatment with medication interfering with the calcium metabolism.
Comparison of Trunk Muscle Performance Between Sprinters With and Without Hamstring Strain Injury History

The aim of this study is to:

1. Compare trunk muscle performance between sprinters with and without HSI history
2. Investigate whether running speed influences the differences on trunk muscle activity between these two groups

Hamstring strain injury is one of the most common injuries in the lower extremities. As running speed increases, the force and load on the hamstring muscles significantly increase, thereby increasing the risk of injury. Trunk muscles are connected thigh muscles through the pelvis, and poor trunk muscle capacity of maintaining stability affect the muscle length of the lower limbs during movement, reducing their contractile tension and increasing the risk of injury. Earlier literature also indicated that poor trunk muscle performance is related to the occurrence of lower extremity sport injuries. However, literature on the relationship between trunk muscle performance and hamstring strain injury is scarce. Testing methods of existing research have failed to fully reflect the actual circumstances of sprinting. Moreover, previous studies have predominantly focused on soccer players. However, the running mechanics of soccer player and sprinter are slightly different. Currently, there is lack of research investigate the relationship between trunk muscle performance and hamstring strain injury in sprinters.Therefore, the aim of this study is to: (1) Compare trunk muscle performance between sprinters with and without HSI history, (2) nvestigate whether running speed influences the differences on trunk muscle activity between these two groups

Eligibility Criteria:
Inclusion Criteria of HSI history group:

* Have ≥ twice hamstring strain injury occurrence in the past year

Inclusion Criteria of control group:

* Without any hamstring strain injury occurrence in the past year
* Match gender, age, BMI, dominant side, training experience, training frequency, Personal best record in 100m with HSI history group

Exclusion Criteria of all subjects:

* Neurological, cardiorespiratory or systemic disorder
* Have low back pain history in the past year
* Scoliosis
* Sacroiliac joint dysfunction
* Complaints of pain on trunk \& lower extremity
* Leg length difference \> 2cm
* History of lower extremity surgery
A Study of LY3484356 in Women With Breast Cancer Before Having Surgery

The purpose for this study is to see if the study drug, LY3484356, is safe and to determine what effects it has on breast cancer in participants with Estrogen Receptor Positive (ER+), HER2 Negative (HER2-) early stage (stage I-III) breast cancer, when given prior to surgery. Participation in this study could last up to 2.5 months.


Eligibility Criteria:
Inclusion Criteria:

* Have histologically confirmed invasive ER+, HER2- breast carcinoma
* Be willing and able to provide pre- and on-treatment tumor samples
* Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group scale
* Have adequate organ function
* Be able to swallow capsules
* Be a postmenopausal woman

Exclusion Criteria:

* Have bilateral invasive breast cancer
* Have metastatic breast cancer
* Plan to receive concurrent neoadjuvant therapy with any other non-protocol anti-cancer therapy
* Have had prior therapy (of any kind) for an invasive or non-invasive breast cancer
* Have had prior radiotherapy to the ipsilateral chest wall for any malignancy
* Have had prior anti-estrogen therapy with raloxifene, tamoxifen, aromatase inhibitor, or other selective estrogen receptor modulator (SERM), either for osteoporosis or prevention of breast cancer
* Have had prior hormone-replacement therapy within 4 weeks of the start of study treatment
* Have had major surgery within 28 days prior to randomization to allow for post-operative healing of the surgical wound and site(s)
* Have certain infections such as hepatitis or tuberculosis or HIV that are not well controlled
* Have another serious medical condition
* Have a history of any other cancer (except nonmelanoma skin cancer or carcinoma in-situ of the cervix), unless in complete remission with no therapy for a minimum of 3 years